Clinical Trials Browser

Completed × osimertinib × Clear all

NCT04479306 2026-04-16

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06525246 2026-03-13

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02917993 2026-02-09

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Inhibition, Psychological, Lung Neoplasms, Neoplasm Metastasis

NCT03133546 2026-02-06

BOOSTER

Phase 2 Completed

155 enrolled 23 charts

Non Small Cell Lung Cancer Metastatic

NCT04184921 2026-02-03

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-01-09

FLAURA

Phase 3 Completed

674 enrolled 21 charts 2 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT02442349 2026-01-09

AURA17

Phase 2 Completed

171 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT04563871 2026-01-09

BLOSSOM

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03810807 2025-12-23

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT07271446 2025-12-09

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02157883 2025-11-19

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Phase 1 Completed

39 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05954871 2025-11-13

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Phase 1 Completed

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03755102 2025-05-15

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Phase EARLY_PHASE1 Completed

Lung Neoplasms

NCT06613633 2025-04-20

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Carcinoma, Non-Small-Cell Lung

NCT04720976 2025-04-11

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

Other solid neoplasmThoracic

Solid Tumor

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT05298176 2025-03-28

COMBINATION

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03543683 2025-02-27

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03414814 2025-02-11

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

Phase 2 Completed

15 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT04233021 2025-02-03

ORBITAL

Phase 2 Completed

Brain Neoplasms, Meningeal Carcinomatosis

NCT02841579 2025-01-28

AZENT

Phase 2 Completed

22 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT02151981 2025-01-07

AURA3

Phase 3 Completed

421 enrolled 18 charts

Anticancer Treatment

NCT03732352 2024-11-12

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Phase 2 Completed

Glioblastoma

NCT02094261 2024-11-06

AURA2

Phase 2 Completed

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03239340 2024-10-21

ELIOS

Phase 2 Completed

154 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02454933 2024-09-19

CAURAL

Phase 3 Completed

29 enrolled 10 charts

Locally Advanced or Metastatic EGFR T790M+ NSCLC

NCT02520778 2024-08-21

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Completed

Advanced Lung Non-Squamous Non-Small Cell Carcinoma

NCT04764214 2024-08-19

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT04770688 2024-08-15

AUTOMAN

Phase 1/2 Completed

Adenocarcinoma of Lung, Neoplasm Metastasis

NCT02759835 2024-06-07

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Phase 2 Completed

37 enrolled 23 charts

Adenocarcinoma of Lung, Lung Neoplasms

NCT03497767 2024-05-31

OUTRUN

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03810066 2024-05-09

Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)

Phase 2 Completed

NSCLC

NCT03535363 2024-03-13

Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02789345 2024-02-05

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Phase 1 Completed

29 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02163733 2024-01-22

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Phase 1 Completed

38 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01802632 2024-01-18

AURA

Phase 1/2 Completed

603 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT02923947 2023-11-27

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

Phase 1 Completed

Renal Insufficiency

NCT04965701 2023-11-13

FLOWER

EGF-R Positive Non-Small Cell Lung Cancer

NCT03434418 2023-10-17

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Phase 2 Completed

17 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT02803203 2023-09-22

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Phase 1/2 Completed

49 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04959981 2023-07-25

HERKULES-2

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Noonan Syndrome, Thoracic Neoplasms

NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Phase 1/2 Completed

113 enrolled 22 charts

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT04179890 2023-05-25

UpSwinG

462 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT04541407 2023-05-16

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT03455829 2023-05-06

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Phase 1/2 Completed

30 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03463525 2023-01-27

ODIN-BM

Phase 1 Completed

4 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02908750 2022-11-14

Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03790397 2022-06-03

OSIREX

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03219970 2021-09-14

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Carcinoma, Non-Small-Cell Lung

NCT02769286 2021-08-03

LiquidLung-O

Phase 2 Completed

Lung Neoplasms